Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)

NCT07509151 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07509151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07509151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
May 5, 2026
Completion date
April 5, 2032
Enrollment
420 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia or small lymphocytic lymphoma with unmutated ighv